SEC Form 4 · accession 0002124509-26-000004
Revolution Medicines, Inc. · RVMD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Anthony Mancini
Officer — See Remarks
Period of report
Sep 10, 2026
Accepted (ET)
Sep 14, 2026 · 6:03 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001628171
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 10, 2026 | M | 9,363 | $33.62 | A | 59,338 | D | |
| Common StockF2 | Sep 10, 2026 | S | 6,019 | $203.2844 | D | 53,319 | D | |
| Common StockF3 | Sep 10, 2026 | S | 5,530 | $204.1357 | D | 47,789 | D | |
| Common StockF4 | Sep 10, 2026 | S | 2,420 | $205.0513 | D | 45,369 | D | |
| Common StockF5 | Sep 10, 2026 | S | 1,179 | $206.0995 | D | 44,190 | D | |
| Common StockF6,F7 | Sep 10, 2026 | S | 300 | $207.1733 | D | 43,890 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F8 | $33.62 | Sep 10, 2026 | M | 9,363 | D | — | Mar 31, 2035 | Common Stock | 9,363 | 96,746 | D |
Explanation of responses
- F1Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on June 11, 2026.
- F2The transaction was executed in multiple trades at prices ranging from $202.64 to $203.63, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F3The transaction was executed in multiple trades at prices ranging from $203.64 to $204.63, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F4The transaction was executed in multiple trades at prices ranging from $204.64 to $205.55, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F5The transaction was executed in multiple trades at prices ranging from $205.85 to $206.70, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F6The transaction was executed in multiple trades at prices ranging from $207.12 to $207.28, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F7Includes 43,700 restricted stock units.
- F8Twenty-five percent of the total shares subject to the option will vest on the first year anniversary measured from April 1, 2025 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary of the Vesting Commencement Date thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.
Remarks
Chief Global Commercialization Officer